Context Therapeutics Inc Stock Price, News & Analysis

Context Therapeutics Inc. (Nasdaq: CNTX) announced that CEO Martin Lehr will present at the Sachs 15th Annual European Life Sciences CEO Forum on March 1-2, 2022, with on-demand viewing available. The company will also engage in one-on-one meetings from February 28 to March 4, 2022. Context focuses on developing small molecule and immunotherapy treatments for breast and gynecological cancers, particularly its lead candidate, ONA-XR, which is undergoing several clinical trials. For more details, visit their website.

Context Therapeutics announced the appointments of Christopher Beck as SVP of Operations and Mark Fletcher, Ph.D. as VP of R&D, effective January 5, 2022. These appointments come as the company approaches pivotal phases in its pipeline, particularly with its lead product candidate ONA-XR for treating women's cancers. The current Head of CMC, Bill Rencher, Ph.D., will transition to an advisory role. The new leadership team aims to advance research and development initiatives within the company, focusing on effective treatments for hormone-driven cancers.

Context Therapeutics (Nasdaq: CNTX), a women's oncology company, announced that CEO Martin Lehr will participate in two upcoming investor conferences in January 2022. The Biotech Showcase™ 2022 conference is set for January 10-12, with Lehr's panel on women's health scheduled for January 12 at 8 a.m. PST. Additionally, Context will present at the Edison Group Open House: Global Healthcare 2022 from January 25-27 and will hold one-on-one meetings. Context is focused on developing treatments for breast and gynecological cancers, with ongoing clinical trials for its lead candidate, ONA-XR.

Context Therapeutics Inc. (Nasdaq: CNTX) announced promising data from the ONAWA trial at the 2021 San Antonio Breast Cancer Symposium. The trial evaluated onapristone extended release (ONA-XR) in postmenopausal women with PR+ early breast cancer. Results indicated a significant decrease in tumor cell proliferation, especially in tumors with high PR expression. Additionally, two other trials on ONA-XR for metastatic breast cancer were presented. The data suggest ONA-XR's potential as a therapeutic option for hormone-driven cancers, with further evaluations planned in 2022.

Context Therapeutics (Nasdaq: CNTX) has successfully closed a private placement, raising approximately $31.25 million by selling 5,000,000 shares of common stock along with 5,000,000 warrants. Each share and warrant were offered at a combined price of $6.25, with a warrant exercise price also set at $6.25 and a term of five and a half years. The proceeds will enhance the company’s oncology treatment initiatives, particularly its lead candidate, ONA-XR, aimed at tackling hormone-driven breast and gynecological cancers.

Context Therapeutics Inc. (Nasdaq: CNTX) announced a $31.25 million private placement and raised $28.75 million from its IPO. The company focuses on developing treatments for breast and gynecological cancers and has initiated patient dosing in a Phase 2 clinical trial targeting ER+, PR+, HER2- metastatic breast cancer. Recent financial results report a net loss of $1.4 million for Q3 2021 and increased R&D and G&A expenses. Context expects its financial resources will sustain operations until 2024, with ongoing clinical trials for its lead candidate, ONA-XR.

Context Therapeutics (Nasdaq: CNTX) announced a private placement, securing approximately $31.25 million from the sale of 5,000,000 shares of common stock and warrants to purchase an additional 5,000,000 shares. Each share and accompanying warrant are priced at $6.25. The placement is set to close on December 6, 2021, subject to usual conditions. The shares and warrants will not be registered under the Securities Act and may not be sold in the U.S. without registration or an exemption. Context is focused on innovating treatments for breast and gynecological cancers.

Context Therapeutics (Nasdaq: CNTX) announced that clinical data for ONA-XR will be presented at the 2021 San Antonio Breast Cancer Symposium from December 7-10, 2021. The presentations will include primary results from the ONAWA trial, focusing on early-stage breast cancer, as well as updates from ongoing trials in metastatic breast cancer. ONA-XR targets progesterone receptor-positive cancers and is currently undergoing multiple Phase 1b and Phase 2 trials. The company aims to highlight the drug's potential impact on treatment outcomes.

Context Therapeutics has appointed Jennifer Minai-Azary as Chief Financial Officer and Alex Levit as Chief Legal Officer, as announced on November 1, 2021. This leadership change follows the company's recent debut on Nasdaq and aims to strengthen its position in developing treatments for hormone-driven women's cancers. Minai-Azary, with over 20 years of experience, previously served as CFO at Millendo Therapeutics, while Levit brings nearly two decades of legal expertise in the biopharma sector. Both executives are expected to drive the company's strategic growth and clinical milestones.